Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice

Nicole A. Rozette, Suraporn Matragoon, Shivani Sethi, Stephanie Goei, Kalen B. Manasco, Azza B. El-Remessy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Cyclopentolate is standardly used in ophthalmologic examinations of neonates to facilitate screening for retinopathy of prematurity. Reports of systemic effects have raised concerns of an increased risk of feeding intolerance after the examinations. Objectives: The goal of this study was to evaluate systemic concentrations of cyclopentolate after ophthalmic administration, as well as assess changes in weight as an indirect measure of alteration in feeding. Methods: Neonatal mice were randomized into three groups to simulate a neonatal model for ophthalmic medication administration. The cyclopentolate group received a one-time administration of tetracaine, cyclopentolate, and phenylephrine ophthalmologic solutions in accordance with the protocol used at the children's hospital. The placebo group received the same ophthalmic drop administration, except for normal saline in place of cyclopentolate, and the control group received no ophthalmic drops and minimal handling. Daily weights and serum samples to measure systemic concentrations of cyclopentolate post-ophthalmic administration were assessed at baseline and for 7 days following drop administration. Results: Analysis of serum levels demonstrated detectability of systemic cyclopentolate after ophthalmic administration as early as 30 min (86 ng/ml), 1 h (60 ng/ml), and 24 h (6.2 ng/ml). There were also differences in weight gained on following ophthalmic administration observed between the cyclopentolate group and placebo group, with the cyclopentolate group weighing significantly less on days 3 and 7 (p = 0.02). Conclusions: Results indicate cyclopentolate is absorbed systemically and instillation of cyclopentolate decreases weight gain in neonatal mice compared to placebo. These preclinical findings provide rationale for further studies in neonatal patients.

Original languageEnglish (US)
Pages (from-to)37-41
Number of pages5
JournalNeonatology
Volume106
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Cyclopentolate
Ophthalmic Administration
Body Weight
Ophthalmic Solutions
Placebos
Weights and Measures
Tetracaine
Retinopathy of Prematurity
Phenylephrine
Serum
Weight Gain

Keywords

  • Adverse drug reactions
  • Animal model
  • Feeding intolerance
  • Neonates
  • Ophthalmic cyclopentolate
  • Premature infants
  • Retinopathy of prematurity
  • Systemic cyclopentolate

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental Biology

Cite this

Rozette, N. A., Matragoon, S., Sethi, S., Goei, S., Manasco, K. B., & El-Remessy, A. B. (2014). Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice. Neonatology, 106(1), 37-41. https://doi.org/10.1159/000358228

Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice. / Rozette, Nicole A.; Matragoon, Suraporn; Sethi, Shivani; Goei, Stephanie; Manasco, Kalen B.; El-Remessy, Azza B.

In: Neonatology, Vol. 106, No. 1, 01.01.2014, p. 37-41.

Research output: Contribution to journalArticle

Rozette, NA, Matragoon, S, Sethi, S, Goei, S, Manasco, KB & El-Remessy, AB 2014, 'Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice', Neonatology, vol. 106, no. 1, pp. 37-41. https://doi.org/10.1159/000358228
Rozette NA, Matragoon S, Sethi S, Goei S, Manasco KB, El-Remessy AB. Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice. Neonatology. 2014 Jan 1;106(1):37-41. https://doi.org/10.1159/000358228
Rozette, Nicole A. ; Matragoon, Suraporn ; Sethi, Shivani ; Goei, Stephanie ; Manasco, Kalen B. ; El-Remessy, Azza B. / Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice. In: Neonatology. 2014 ; Vol. 106, No. 1. pp. 37-41.
@article{46ff0469689b4bd38dc152aa00679354,
title = "Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice",
abstract = "Background: Cyclopentolate is standardly used in ophthalmologic examinations of neonates to facilitate screening for retinopathy of prematurity. Reports of systemic effects have raised concerns of an increased risk of feeding intolerance after the examinations. Objectives: The goal of this study was to evaluate systemic concentrations of cyclopentolate after ophthalmic administration, as well as assess changes in weight as an indirect measure of alteration in feeding. Methods: Neonatal mice were randomized into three groups to simulate a neonatal model for ophthalmic medication administration. The cyclopentolate group received a one-time administration of tetracaine, cyclopentolate, and phenylephrine ophthalmologic solutions in accordance with the protocol used at the children's hospital. The placebo group received the same ophthalmic drop administration, except for normal saline in place of cyclopentolate, and the control group received no ophthalmic drops and minimal handling. Daily weights and serum samples to measure systemic concentrations of cyclopentolate post-ophthalmic administration were assessed at baseline and for 7 days following drop administration. Results: Analysis of serum levels demonstrated detectability of systemic cyclopentolate after ophthalmic administration as early as 30 min (86 ng/ml), 1 h (60 ng/ml), and 24 h (6.2 ng/ml). There were also differences in weight gained on following ophthalmic administration observed between the cyclopentolate group and placebo group, with the cyclopentolate group weighing significantly less on days 3 and 7 (p = 0.02). Conclusions: Results indicate cyclopentolate is absorbed systemically and instillation of cyclopentolate decreases weight gain in neonatal mice compared to placebo. These preclinical findings provide rationale for further studies in neonatal patients.",
keywords = "Adverse drug reactions, Animal model, Feeding intolerance, Neonates, Ophthalmic cyclopentolate, Premature infants, Retinopathy of prematurity, Systemic cyclopentolate",
author = "Rozette, {Nicole A.} and Suraporn Matragoon and Shivani Sethi and Stephanie Goei and Manasco, {Kalen B.} and El-Remessy, {Azza B.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000358228",
language = "English (US)",
volume = "106",
pages = "37--41",
journal = "Neonatology",
issn = "1661-7800",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Systemic effects of ophthalmic cyclopentolate on body weight in neonatal mice

AU - Rozette, Nicole A.

AU - Matragoon, Suraporn

AU - Sethi, Shivani

AU - Goei, Stephanie

AU - Manasco, Kalen B.

AU - El-Remessy, Azza B.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Cyclopentolate is standardly used in ophthalmologic examinations of neonates to facilitate screening for retinopathy of prematurity. Reports of systemic effects have raised concerns of an increased risk of feeding intolerance after the examinations. Objectives: The goal of this study was to evaluate systemic concentrations of cyclopentolate after ophthalmic administration, as well as assess changes in weight as an indirect measure of alteration in feeding. Methods: Neonatal mice were randomized into three groups to simulate a neonatal model for ophthalmic medication administration. The cyclopentolate group received a one-time administration of tetracaine, cyclopentolate, and phenylephrine ophthalmologic solutions in accordance with the protocol used at the children's hospital. The placebo group received the same ophthalmic drop administration, except for normal saline in place of cyclopentolate, and the control group received no ophthalmic drops and minimal handling. Daily weights and serum samples to measure systemic concentrations of cyclopentolate post-ophthalmic administration were assessed at baseline and for 7 days following drop administration. Results: Analysis of serum levels demonstrated detectability of systemic cyclopentolate after ophthalmic administration as early as 30 min (86 ng/ml), 1 h (60 ng/ml), and 24 h (6.2 ng/ml). There were also differences in weight gained on following ophthalmic administration observed between the cyclopentolate group and placebo group, with the cyclopentolate group weighing significantly less on days 3 and 7 (p = 0.02). Conclusions: Results indicate cyclopentolate is absorbed systemically and instillation of cyclopentolate decreases weight gain in neonatal mice compared to placebo. These preclinical findings provide rationale for further studies in neonatal patients.

AB - Background: Cyclopentolate is standardly used in ophthalmologic examinations of neonates to facilitate screening for retinopathy of prematurity. Reports of systemic effects have raised concerns of an increased risk of feeding intolerance after the examinations. Objectives: The goal of this study was to evaluate systemic concentrations of cyclopentolate after ophthalmic administration, as well as assess changes in weight as an indirect measure of alteration in feeding. Methods: Neonatal mice were randomized into three groups to simulate a neonatal model for ophthalmic medication administration. The cyclopentolate group received a one-time administration of tetracaine, cyclopentolate, and phenylephrine ophthalmologic solutions in accordance with the protocol used at the children's hospital. The placebo group received the same ophthalmic drop administration, except for normal saline in place of cyclopentolate, and the control group received no ophthalmic drops and minimal handling. Daily weights and serum samples to measure systemic concentrations of cyclopentolate post-ophthalmic administration were assessed at baseline and for 7 days following drop administration. Results: Analysis of serum levels demonstrated detectability of systemic cyclopentolate after ophthalmic administration as early as 30 min (86 ng/ml), 1 h (60 ng/ml), and 24 h (6.2 ng/ml). There were also differences in weight gained on following ophthalmic administration observed between the cyclopentolate group and placebo group, with the cyclopentolate group weighing significantly less on days 3 and 7 (p = 0.02). Conclusions: Results indicate cyclopentolate is absorbed systemically and instillation of cyclopentolate decreases weight gain in neonatal mice compared to placebo. These preclinical findings provide rationale for further studies in neonatal patients.

KW - Adverse drug reactions

KW - Animal model

KW - Feeding intolerance

KW - Neonates

KW - Ophthalmic cyclopentolate

KW - Premature infants

KW - Retinopathy of prematurity

KW - Systemic cyclopentolate

UR - http://www.scopus.com/inward/record.url?scp=84899591040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899591040&partnerID=8YFLogxK

U2 - 10.1159/000358228

DO - 10.1159/000358228

M3 - Article

C2 - 24776747

AN - SCOPUS:84899591040

VL - 106

SP - 37

EP - 41

JO - Neonatology

JF - Neonatology

SN - 1661-7800

IS - 1

ER -